EUVIMEDEUVIMED entdecken
Crossref

Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast Cancer

Ayse Mine Yilmaz Goler, Ayse Tarbin Jannuzzi, Abanish Biswas, Subodh Mondal, Vinay N Basavanakatti, Raghusrinivasan Jayaprakash Venkatesan, Hatice Yıldırım, Mahmut Yıldız, Hülya Çelik Onar, Nilüfer Bayrak, Venkatesan Jayaprakash, Amaç Fatih TuYuN

Chemistry & Biodiversity · 2023

DOI: 10.1002/cbdv.202300848 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2023. Verfasst von Ayse Mine Yilmaz Goler und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Medicine/Genetic and Metabolic Diseases Research and Investigation Center, Marmara University, 34854, İstanbul,…. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Colonic Neoplasms, Prostatic Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: National Cancer Institute (NCI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is quite challenging to find out bioactive molecules in the vast chemical universe. Quinone moiety is a unique structure with a variety of biological properties, particularly in the treatment of cancer. In an effort to develop potent and secure antiproliferative lead compounds, five quinolinequinones ( AQQ1‐5 ) described previously have been selected and submitted to the National Cancer Institute (NCI) of Bethesda to envisage their antiproliferative profile based on the NCI Developmental Therapeutics Program. According to the preliminary in vitro single‐dose anticancer screening, four of five quinolinequinones ( AQQ2‐5 ) were selected for five‐dose screening and they displayed promising antiproliferative effects against several cancer types. All AQQs showed a excellent anticancer profile with low micromolar GI 50 and TGI values against all leukemia cell lines, some non‐small cell lung and ovarian cancer, most colon, melanoma, and renal cancer, and in addition to some breast cancer cell lines. AQQ2‐5 reduced the proliferation of all leukemia cell lines at a single dose and five additional doses, as well as some non‐small cell lung and ovarian cancer, the majority of colon cancer, melanoma and renal cancer, and some breast cancer cell lines. This motivated us to use in vitro , in silico , and in vivo technologies to further investigate their mode of action. We investigated the in vitro cytotoxic activities of the most promising compounds, AQQ2 and AQQ3 , in HCT‐116 colon cancer, MCF7 and T‐47D breast cancer, and DU‐145 prostate cancer cell lines, and HaCaT human keratinocytes. Concomitantly, IC 50 values of AQQ2 and AAQ3 against MCF7 and T‐47D cell lines of breast cancer, DU‐145 cell lines of prostate cancer, HCT‐116 cell lines of colon cancer, and HaCaT human keratinocytes were determined. AQQ2 exhibited anticancer activity through the induction of apoptosis and caused alterations in the cell cycle. In silico pharmacokinetic studies of all analogs have been carried out against ATR, CHK1, WEE1, CDK1, and CDK2. In addition to this, in vitro ADME and in vivo pharmacokinetic profiling for the most effective AAQ ( AAQ2 ) have been studied.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic AgentsColonic NeoplasmsProstatic NeoplasmsKidney NeoplasmsMelanomaOvarian NeoplasmsLeukemiaHumansMaleFemaleMolecular StructureStructure-Activity RelationshipCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorMolecular Docking SimulationDose-Response Relationship, Drug

Stichwörter der Autor:innen

ADMEbreast cancercytotoxicitymolecular docking

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Biochemistry, School of Medicine/Genetic and Metabolic Diseases Research and Investigation Center, Marmara University, 34854, İstanbul, Türkiye.
  • Department of Pharmaceutical Toxicology, Faculty of Pharmacy, İstanbul University, 34116, İstanbul, Türkiye.
  • Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, 835215, Ranchi, Jharkhand, India.
  • Bioanalysis, Eurofins Advinus BioPharma Services India Pvt Ltd., 560058, Bengaluru, India.
  • Adgyl Lifesciences Private Limited, 560058, Bengaluru, India.
  • Department of Industrial and Systems Engineering, Faculty of Interdisciplinary Sciences & Engineering, Indian Institute of Technology, 721302, Kharagpur, India.

Förderung

  • National Cancer Institute (NCI)

Zitieren

APA

Yilmaz Goler, A. M., Tarbin Jannuzzi, A., Biswas, A., Mondal, S., Basavanakatti, V. N., Jayaprakash Venkatesan, R., Yıldırım, H., Yıldız, M., Çelik Onar, H., Bayrak, N., Jayaprakash, V., & TuYuN, A. F. (2023). Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast Cancer. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202300848

Vancouver

Yilmaz Goler AM, Tarbin Jannuzzi A, Biswas A, Mondal S, Basavanakatti VN, Jayaprakash Venkatesan R, et al. Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast Cancer. Chemistry & Biodiversity. 2023. doi:10.1002/cbdv.202300848

BibTeX
@article{YilmazGoler2023,
  author = {Yilmaz Goler, Ayse Mine and Tarbin Jannuzzi, Ayse and Biswas, Abanish and Mondal, Subodh and Basavanakatti, Vinay N and Jayaprakash Venkatesan, Raghusrinivasan and Yıldırım, Hatice and Yıldız, Mahmut and Çelik Onar, Hülya and Bayrak, Nilüfer and Jayaprakash, Venkatesan and TuYuN, Amaç Fatih},
  title = {Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast Cancer},
  journal = {Chemistry & Biodiversity},
  year = {2023},
  doi = {10.1002/cbdv.202300848}
}
Kostenlos starten →